Histone Modifications: Implications in Renal Cell Carcinoma

Overview

Journal Epigenomics

Specialty Genetics

Date 2013 Jul 31

PMID 23895657

Citations 13

Authors

Swathi Ramakrishnan

Leigh Ellis

Roberto Pili

Affiliations

Soon will be listed here.

Abstract

In 2012, an estimated 64,770 men and women were diagnosed with malignancy of the kidney and renal pelvis, of which 13,570 succumbed to their disease. Common genetic aberrations in renal cell carcinomas (RCCs) include loss of function of the VHL gene in clear-cell RCC, overexpression of the c-MET gene in papillary RCC type I, deficiency in the FH gene in papillary RCC type II and loss of heterozygozity of the BHD gene in chromophobe RCC. Recent studies illustrate epigenetic silencing of VHL, as well as alterations in histone modifications and their governing enzymes. The possibility of reversing these epigenetic marks has resulted in efforts to target these changes by utilizing inhibitors of HDACs, DNA methyltransferases and, recently, histone methyltransferases in preclinical and clinical studies. This article focuses on potential therapeutic interventions, and the implications of histone modifications and related enzyme alterations in RCC.

Citing Articles

Unravelling the Role of PARP1 in Homeostasis and Tumorigenesis: Implications for Anti-Cancer Therapies and Overcoming Resistance.

Lovsund T, Mashayekhi F, Fitieh A, Stafford J, Ismail I Cells. 2023; 12(14).

PMID: 37508568 PMC: 10378431. DOI: 10.3390/cells12141904.

Endoplasmic Reticulum Stress-Related Signature Predicts Prognosis and Drug Response in Clear Cell Renal Cell Carcinoma.

Zhang Y, Song Y, Dai J, Wang Z, Zeng Y, Chen F Front Pharmacol. 2022; 13:909123.

PMID: 35959432 PMC: 9360548. DOI: 10.3389/fphar.2022.909123.

The clinical significance of epigenetic and RNAPII variabilities occurring in clear cell renal cell carcinoma as a potential prognostic marker.

Ordog N, Borsos B, Majoros H, Ujfaludi Z, Pankotai-Bodo G, Banko S Transl Oncol. 2022; 20:101420.

PMID: 35417813 PMC: 9018449. DOI: 10.1016/j.tranon.2022.101420.

The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments.

Angulo J, Manini C, Lopez J, Pueyo A, Colas B, Ropero S Cancers (Basel). 2021; 13(9).

PMID: 33922974 PMC: 8123355. DOI: 10.3390/cancers13092071.

Optimized Combination of HDACI and TKI Efficiently Inhibits Metabolic Activity in Renal Cell Carcinoma and Overcomes Sunitinib Resistance.

Rausch M, Weiss A, Zoetemelk M, Piersma S, Jimenez C, van Beijnum J Cancers (Basel). 2020; 12(11).

PMID: 33126775 PMC: 7693411. DOI: 10.3390/cancers12113172.

References

Li E . Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet. 2002; 3(9):662-73. DOI: 10.1038/nrg887. View

Turner B . Histone acetylation and an epigenetic code. Bioessays. 2000; 22(9):836-45. DOI: 10.1002/1521-1878(200009)22:9<836::AID-BIES9>3.0.CO;2-X. View

Ellis L, Atadja P, Johnstone R . Epigenetics in cancer: targeting chromatin modifications. Mol Cancer Ther. 2009; 8(6):1409-20. DOI: 10.1158/1535-7163.MCT-08-0860. View

Tikoo K, Lau S, Monks T . Histone H3 phosphorylation is coupled to poly-(ADP-ribosylation) during reactive oxygen species-induced cell death in renal proximal tubular epithelial cells. Mol Pharmacol. 2001; 60(2):394-402. DOI: 10.1124/mol.60.2.394. View

Chi P, Allis C, Wang G . Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer. 2010; 10(7):457-69. PMC: 3262678. DOI: 10.1038/nrc2876. View

Peterson C, Laniel M . Histones and histone modifications. Curr Biol. 2004; 14(14):R546-51. DOI: 10.1016/j.cub.2004.07.007. View

Chan K, Fang D, Gan H, Hashizume R, Yu C, Schroeder M . The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes Dev. 2013; 27(9):985-90. PMC: 3656328. DOI: 10.1101/gad.217778.113. View

Kurdistani S . Histone modifications as markers of cancer prognosis: a cellular view. Br J Cancer. 2007; 97(1):1-5. PMC: 2359665. DOI: 10.1038/sj.bjc.6603844. View

Wang X, Qian D, Ren M, Kato Y, Wei Y, Zhang L . Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res. 2005; 11(9):3535-42. DOI: 10.1158/1078-0432.CCR-04-1092. View

10.

Furdas S, Kannan S, Sippl W, Jung M . Small molecule inhibitors of histone acetyltransferases as epigenetic tools and drug candidates. Arch Pharm (Weinheim). 2012; 345(1):7-21. DOI: 10.1002/ardp.201100209. View

11.

Kato Y, Yoshimura K, Shin T, Verheul H, Hammers H, Sanni T . Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res. 2007; 13(15 Pt 1):4538-46. DOI: 10.1158/1078-0432.CCR-07-0014. View

12.

Jones J, Juengel E, Mickuckyte A, Hudak L, Wedel S, Jonas D . Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med. 2008; 13(8B):2342-2352. PMC: 6529979. DOI: 10.1111/j.1582-4934.2008.00603.x. View

13.

Fraga M, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G . Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet. 2005; 37(4):391-400. DOI: 10.1038/ng1531. View

14.

Nan X, Ng H, Johnson C, Laherty C, Turner B, Eisenman R . Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998; 393(6683):386-9. DOI: 10.1038/30764. View

15.

Bernt K, Zhu N, Sinha A, Vempati S, Faber J, Krivtsov A . MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell. 2011; 20(1):66-78. PMC: 3329803. DOI: 10.1016/j.ccr.2011.06.010. View

16.

Ajiro K, Nishimoto T . Specific site of histone H3 phosphorylation related to the maintenance of premature chromosome condensation. Evidence for catalytically induced interchange of the subunits. J Biol Chem. 1985; 260(29):15379-81. View

17.

Hakimi A, Ostrovnaya I, Reva B, Schultz N, Chen Y, Gonen M . Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res. 2013; 19(12):3259-67. PMC: 3708609. DOI: 10.1158/1078-0432.CCR-12-3886. View

18.

Koh C, Iwata T, Zheng Q, Bethel C, Yegnasubramanian S, De Marzo A . Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget. 2011; 2(9):669-83. PMC: 3248223. DOI: 10.18632/oncotarget.327. View

19.

Kleer C, Cao Q, Varambally S, Shen R, Ota I, Tomlins S . EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A. 2003; 100(20):11606-11. PMC: 208805. DOI: 10.1073/pnas.1933744100. View

20.

Bolden J, Peart M, Johnstone R . Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006; 5(9):769-84. DOI: 10.1038/nrd2133. View